Navigation Links
Affordable medicine plan goes global
Date:11/14/2008

An innovative plan to get new life-saving drugs into the hands of millions of people around the world who need medicines but can't afford the massive costs will be unveiled to key decision makers in London and Washington over the coming weeks.

"Pharmaceuticals have become an increasingly important part of health care, and you see that in the soaring amounts of money spent on them in developed countries like Canada and developing countries," says Aidan Hollis, an associate professor of economics at the University of Calgary and a key architect of the Health Impact Fund.

The steep cost of drugs has contributed to the deaths of millions of people in the developing world from diseases such as HIV-AIDS says Hollis. "And we're seeing this now play out with many new cancer-care drugs that are priced at a level even people in developed countries can't afford."

The Health Impact Fund, devised by Hollis and Thomas Pogge, Leitner Professor of philosophy and international affairs at Yale, will be presented to key government leaders, international aid agencies, NGOs, and pharmaceutical company representatives at Oxford, Cambridge, London, and Georgetown universities over the next three weeks.

"Currently, funding for drug innovation is based on people in rich countries paying taxes and drug insurance premiums to cover the exorbitant costs. Unfortunately, to sustain this system, poor people get excluded and the world is mainly comprised of poor people," says Hollis.

Hollis and Pogge propose a 'pay for performance' scheme in which drug companies would have the option to register their products with the HIF and sell the product for no more than the cost of production and distribution. In exchange, they would receive a stream of payments based on the assessed global health impact of each drug. The bigger the impact on worldwide health, the bigger the payout. And if there's no measurable health impact, there's no reward. Firms would only register their products if they expected to earn more from the HIF than from selling their products at high prices.

"The idea is that it's not the responsibility of the drug companies to ensure that everyone has access to these medicines. Charity by for-profit companies is not a sustainable solution," says Hollis. "By reorganizing the way we pay for pharmaceutical innovation, we can achieve wider access without extra costs. Patients win, and pharmaceutical companies also win."

Peter Singer, a bioethics professor at Princeton University and one of many collaborators involved in the project says: "The beauty of the scheme is that it gives economic support to the idea that all human lives are of equal value."

The estimated cost of this fund would be $6-billion annually, paid through a consortium of governments. Patients and insurance companies would then cover only the marginal cost of production and distribution. The key is getting buy-in from a number of governments worldwide.

Hollis admits that the timing is bad to be asking for cash during the current global economic crisis when the attention of the world's governments is focused elsewhere. But that doesn't mean the critical issue of drug accessibility is going away. "The U.S. has nearly 50 million people without health insurance who may not be getting the drugs they need and that's likely to increase with the weaker economy."

Pogge says Barack Obama's recent presidential election win suggests that the U.S. is more likely to be interested in such a proposal, which presents a unique opportunity for the country to regain some of the good will and moral stature it has lost in recent years.

"One very big difference this financial crisis makes is that we have to emphasize that the Health Impact Fund is advantageous for both rich and poor countries. It mustn't be perceived as merely a development-aid project. And I think that's relatively easy to do because in rich countries we also have problems with expensive drugs that insurance companies and national health systems won't pay for."

"Everyone can benefit when we treat research and development of pharmaceuticals as a global public good."


'/>"/>

Contact: James Stevenson
jlsteve@ucalgary.ca
403-210-6308
University of Calgary
Source:Eurekalert

Related medicine news :

1. PharmacyChecker.com Publishes Safe Strategies for Drug Savings to Help All Americans Get Affordable Medication
2. DRE Medical Equipment Adds Affordable Refurbished Ultrasound Machines to Product Line
3. SEIU Member Will Be in Town Hall Audience, Ready to Ask John McCain Why He Wont Provide Affordable Healthcare for All
4. Catholic Health Initiatives Makes Major Gift to Support Affordable Housing in the Midwest
5. Social Network For Affordable Health Care Supporters Stimulates A New Level of Interactivity and Dialogue
6. Social Network for Affordable Health Care Supporters Stimulates a New Level of Interactivity and Dialogue
7. Quotebroker Expands Territory by Offering Affordable Health Insurance Quotes to Arizona Residents
8. Laboring Without Health Insurance? HSAs May Be an Affordable Option
9. Why Affordable HIV Testing Is More Important Than Ever: "HIV Epidemic 40% Higher Than Estimates"
10. AmeriPlan Offers Affordable Money-Saving Discount Healthcare Programs for the Uninsured and Underinsured
11. Making Healthcare More Affordable Is a National Priority
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: